Antimelanoma Effects of Concomitant Inhibition of SIRT1 and SIRT3 in Braf^V600E/Pten^NULL Mice.

ABSTRACT: Novel therapeutic strategies are required for the effective and lasting treatment of metastatic melanoma, one of the deadliest skin malignancies. In this study, we determined the antimelanoma efficacy of 4'-bromo-resveratrol (4'-BR), which is a small-molecule dual inhibitor of SIRT1 and SIRT3, in a Braf^V600E/Pten^NULL mouse model that recapitulates human disease, including metastases. Tumors were induced by topical application of 4-hydroxy-tamoxifen on shaved backs of mice aged 10 weeks, and the effects of 4'-BR (5‒30 mg/kg of body weight, intraperitoneally, 3 days per week for 5 weeks) were assessed on melanoma development and progression. We found that 4'-BR at a dose of 30 mg/kg significantly reduced the size and volume of primary melanoma tumors as well as lung met

SUBMITTER: Chhabra G 

PROVIDER: S-EPMC9199498 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature